Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14242185 | 0.82 | NOTUM (0.42) | SMN1; SMN2MAPTRAB9ANPC1HPGD | |
| SCHEMBL9892874 | 0.80 | THRB (0.40) | THRBSMN1; SMN2TP53SMYD3MAPT | |
| SCHEMBL2131964 | 0.75 | TP53 (0.50) | THRBSMN1; SMN2TP53SMYD3MAPT | |
| SCHEMBL14242692 | 0.75 | RAB9A (0.41) | THRBSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL2619071 | 0.73 | THRB (0.48) | THRBSMN1; SMN2TP53SMYD3MAPT | |
| SCHEMBL16571478 | 0.73 | THRB (0.41) | THRBSMN1; SMN2TP53SMYD3MAPT | |
| SCHEMBL2373540 | 0.73 | SMN1; SMN2 (0.49) | THRBSMN1; SMN2TP53SMYD3MAPT | |
| SCHEMBL11533407 | 0.73 | SMN1; SMN2 (0.49) | THRBSMN1; SMN2TP53SMYD3MAPT | |
| SCHEMBL18000496 | 0.71 | — | — | |
| SCHEMBL27247841 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | THRB 1041/4885SMN1; SMN2 4282/4885TP53 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.